With the aging of western society the contribution to morbidity of diseases of the elderly, such as dementia, will increase exponentially. Thorough preventative and curative strategies are needed to constrain the increasing prevalence of these disabling diseases. Better understanding of the pathogenesis of disease will enable development of therapy, prevention and the identification of high-risk groups in the population. Here, we review the genetic epidemiology of Alzheimer’s disease, the most common cause of dementia in the western world. The search for genetic risk factors, though far from completed, has been of major importance for understanding the pathogenesis of Alzheimer’s disease. Although effective therapy is still awaited, these findings have led to new avenues for the development of drugs.

Keywords:
Alzheimer’s disease, Genetic epidemiology, Pathogenesis, Risk prediction, Genetic counselling, β-Amyloid
1.
Roks G, Van Duijn CM: Genetic epidemiology of Alzheimer’s disease; in Bishop T, Sham PM (eds): Analysis of Multifactorial Diseases. Oxford, Bios, 2000, pp 85–100.
2.
St George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al: The genetic defect causing familial Alzheimer’s disease maps on chromosome 21. Science 1987;235:885–890.
3.
Tanzi RE, Gusella JF, Watkins PC, Bruns GA, St George-Hyslop P, Van Keuren ML, Patterson D, Pagan S, Kurnit DM, Neve RL: Amyloid beta protein gene: cDNA, mRNA distribution, and genetic linkage near the Alzheimer locus. Science 1987;235:880–884.
4.
Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al: Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer’s disease. Nature 1991;349:704–706.
5.
Van Broeckhoven CL: Molecular genetics of Alzheimer disease: Identification of genes and gene mutations. Eur Neurol 1995;35:8–19.
6.
Schellenberg GD, Bird TD, Wijsman EM, Orr HT, Anderson L, Nemens E, White JA, Bonnycastle L, Weber JL, Alonso ME, et al: Genetic linkage evidence for a familial Alzheimer’s disease locus on chromosome 14. Science 1992;258:668–671.
7.
St George-Hyslop P, Haines J, Rogaev E, Mortilla M, Vaula G, Pericak-Vance M, Foncin JF, Montesi M, Bruni A, Sorbi S, et al: Genetic evidence for a novel familial Alzheimer’s disease locus on chromosome 14. Nat Genet 1992;2:330–334.
8.
Mullan M, Houlden H, Windelspecht M, Fidani L, Lombardi C, Diaz P, Rossor M, Crook R, Hardy J, Duff K, et al: A locus for familial early-onset Alzheimer’s disease on the long arm of chromosome 14, proximal to the alpha 1-antichymotrypsin gene. Nat Genet 1992;2:340–342.
9.
Van Broeckhoven C, Backhovens H, Cruts M, De Winter G, Bruyland M, Cras P, Martin JJ: Mapping of a gene predisposing to early-onset Alzheimer’s disease to chromosome 14q24.3. Nat Genet 1992;2:335–339.
10.
Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al: Cloning of a gene bearing missense mutations in early-onset familial Alzheimer’s disease. Nature 1995;375:754–760.
11.
Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al: Candidate gene for the chromosome 1 familial Alzheimer’s disease locus. Science 1995;269:973–977.
12.
Rogaev EI, Sherrington R, Rogaeva EA, Levesque G, Ikeda M, Liang Y, Chi H, Lin C, Holman K, Tsuda T, et al: Familial Alzheimer’s disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer’s disease type 3 gene. Nature 1995;376:775–778.
13.
Cummings JL, Benson DF: Cortical dementias: Alzheimer’s disease and other cortical degenerations; in Cummings JL, Benson DF (eds): Dementia: A Clinical Approach. Stoneham, Butterworth-Heinemann, 1992, pp 45–93.
14.
Giacobini E: Cholinesterase inhibitor therapy stabilizes symptoms of Alzheimer disease. Alzheimer Dis Assoc Disord 2000;14:S3–10.
15.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944.
16.
Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
17.
Delacourte A, Buee L: Tau pathology: A marker of neurodegenerative disorders. Curr Opin Neurol 2000;13:371–376.
18.
Rocca WA, Hofman A, Brayne C, Breteler MM, Clarke M, Copeland JR, Dartigues JF, Engedal K, Hagnell O, Heeren TJ, et al: Frequency and distribution of Alzheimer’s disease in Europe: A collaborative study of 1980–1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol 1991;30:381–390.
19.
Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S4–9.
20.
Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, Lobo A, Martinez-Lage J, Soininen H, Hofman A: Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:S10–15.
21.
St George-Hyslop PH: Piecing together Alzheimer’s. Sci Am 2000;283:76–83.
22.
Van Duijn CM: Epidemiology of the dementias: Recent developments and new approaches. J Neurol Neurosurg Psychiatry 1996;60:478–488.
23.
Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Oden A, Swanborg A: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–1145.
24.
Elias MF, Wolf PA, D’Agostino RB, Cobb J, White LR: Untreated blood pressure level is inversely related to cognitive functioning: The Framingham Study. Am J Epidemiol 1993;138:353–364.
25.
Ott A, Slooter AJ, Hofman A, Van Harskamp F, Witteman JC, Van Broeckhoven C, Van Duijn CM, Breteler MM: Smoking and risk of dementia and Alzheimer’s disease in a population-based cohort study: The Rotterdam Study. Lancet 1998;351:1840–1843.
26.
Ott A, Stolk RP, Van Harskamp F, Pols HA, Hofman A, Breteler MM: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999;53:1937–1942.
27.
Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O’Brien PC, Palumbo PJ: Risk of dementia among persons with diabetes mellitus: A population-based cohort study. Am J Epidemiol 1997;145:301–308.
28.
Lee PN: Smoking and Alzheimer’s disease: A review of the epidemiological evidence. Neuroepidemiology 1994;13:131–144.
29.
Merchant C, Tang MX, Albert S, Manly J, Stern Y, Mayeux R: The influence of smoking on the risk of Alzheimer’s disease. Neurology 1999;52:1408–1412.
30.
Brenner DE, Kukull WA, Stergachis A, Van Belle G, Bowen JD, McCormick WC, Teri L, Larson EB: Postmenopausal estrogen replacement therapy and the risk of Alzheimer’s disease: A population-based case-control study. Am J Epidemiol 1994;140:262–267.
31.
Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer’s disease: The Baltimore Longitudinal Study of Aging. Neurology 1997;48:1517–1521.
32.
Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at onset of Alzheimer’s disease. Lancet 1996;348:429–432.
33.
Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, Van Harskamp F, Van Duijn CM, Van Broeckhoven C, Grobbee DE: Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer’s disease in the Rotterdam Study. Lancet 1997;349:151–154.
34.
Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, Gao S, Evans RM, Ogunseyinde AO, Adeyinka AO, Musick B, Hui SL: Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA 2001;285:739–747.
35.
Van Duijn CM, Clayton D, Chandra V, Fratiglioni L, Graves AB, Heyman A, Jorm AF, Kokmen E, Kondo K, Mortimer JA, et al: Familial aggregation of Alzheimer’s disease and related disorders: A collaborative re-analysis of case-control studies. EURODEM Risk Factors Research Group. Int J Epidemiol 1991;20:S13–20.
36.
Plassman BL, Breitner JC: Recent advances in the genetics of Alzheimer’s disease and vascular dementia with an emphasis on gene-environment interactions. J Am Geriatr Soc 1996;44:1242–1250.
37.
Van Duijn CM, Farrer LA, Cupples LA, Hofman A: Genetic transmission of Alzheimer’s disease among families in a Dutch population based study. J Med Genet 1993;30:640–646.
38.
Rao VS, Van Duijn CM, Connor-Lacke L, Cupples LA, Growdon JH, Farrer LA: Multiple etiologies for Alzheimer disease are revealed by segregation analysis. Am J Hum Genet 1994;55:991–1000.
39.
Croes EA, Dermaut B, Van der Cammen TJ, Van Broeckhoven C, Van Duijn CM: Genetic testing should not be advocated as a diagnostic tool in familial forms of dementia. Am J Hum Genet 2000;67:1033–1035.
40.
Cruts M, Van Broeckhoven C: Molecular genetics of Alzheimer’s disease. Ann Med 1998;30:560–565.
41.
Cruts M, Van Duijn CM, Backhovens H, Van den Broeck M, Wehnert A, Serneels S, Sherrington R, Hutton M, Hardy J, St George-Hyslop PH, Hofman A, Van Broeckhoven C: Estimation of the genetic contribution of presenilin-1 and -2 mutations in a population-based study of presenile Alzheimer disease. Hum Mol Genet 1998;7:43–51.
42.
Tol J, Roks G, Slooter AJ, Van Duijn CM: Genetic and environmental factors in Alzheimer’s disease. Rev Neurol (Paris) 1999;155:S10–16.
43.
Pericak-Vance MA, Bebout JL, Gaskell PC Jr, Yamaoka LH, Hung WY, Alberts JM, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, et al: Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am J Hum Genet 1991;48:1034–1050.
44.
Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD: Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci USA 1993;90:1977–1981.
45.
Van Duijn CM, De Knijff P, Cruts M, Wehnert A, Havekes LM, Hofman A, Van Broeckhoven C: Apolipoprotein E4 allele in a population-based study of early-onset Alzheimer’s disease. Nat Genet 1994;7:74–78.
46.
Liddell MB, Lovestone S, Owen MJ: Genetic risk of Alzheimer’s disease: Advising relatives. Br J Psychiatry 2001;178:7–11.
47.
Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, Van Duijn CM: Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta-Analysis Consortium. JAMA 1997;278:1349–1356.
48.
Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when – not whether – one is predisposed to develop Alzheimer disease. Nat Genet 1998;19:321–322.
49.
Golde TE, Eckman CB, Younkin SG: Biochemical detection of Abeta isoforms: Implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease. Biochim Biophys Acta 2000;1502:172–187.
50.
Hardy J: Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci 1997;20:154–159.
51.
Tandon A, Rogaeva E, Mullan M, St George-Hyslop PH: Molecular genetics of Alzheimer’s disease: The role of beta-amyloid and the presenilins. Curr Opin Neurol 2000;13:377–384.
52.
Selkoe DJ: The origins of Alzheimer disease: A is for Amyloid. JAMA 2000;283:1615–1617.
53.
Selkoe DJ: Alzheimer’s disease: A central role for amyloid. J Neuropathol Exp Neurol 1994;53:438–447.
54.
Rosenberg RN: A causal role for amyloid in Alzheimer’s disease: The end of the beginning. Neurology 1993;43:851–856.
55.
Rosenberg RN: The molecular and genetic basis of AD: The end of the beginning: The 2000 Wartenberg lecture. Neurology 2000;54:2045–2054.
56.
Younkin SG: The role of A beta 42 in Alzheimer’s disease. J Physiol Paris 1998;92:289–292.
57.
St George-Hyslop PH: Genetic factors in the genesis of Alzheimer’s disease. Ann NY Acad Sci 2000;924:1–7.
58.
Cao X, Sudhof TC: A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 2001;293:115–120.
59.
Citron M, Vigo-Pelfrey C, Teplow DB, Miller C, Schenk D, Johnston J, Winblad B, Venizelos N, Lannfelt L, Selkoe DJ: Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc Natl Acad Sci USA 1994;91:11993–11997.
60.
Haass C, Hung AY, Selkoe DJ, Teplow DB: Mutations associated with a locus for familial Alzheimer’s disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 1994;269:17741–17748.
61.
Tamaoka A, Odaka A, Ishibashi Y, Usami M, Sahara N, Suzuki N, Nukina N, Mizusawa H, Shoji S, Kanazawa I, et al: APP717 missense mutation affects the ratio of amyloid beta protein species (A beta 1–42/43 and a beta 1–40) in familial Alzheimer’s disease brain. J Biol Chem 1994;269:32721–32724.
62.
Eckman CB, Mehta ND, Crook R, Perez-Tur J, Prihar G, Pfeiffer E, Graff-Radford N, Hinder P, Yager D, Zenk B, Refolo LM, Prada CM, Younkin SG, Hutton M, Hardy J: A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 1997;6:2087–2089.
63.
Jarrett JT, Lansbury PT Jr: Seeding ‘one-dimensional crystallization’ of amyloid: A pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 1993;73:1055–1058.
64.
Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe d, Younkin S: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nat Med 1996;2:864–870.
65.
Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, Johnson-Wood K, Lee M, Seubert P, Davis A, Kholodenko D, Motter R, Sherrington R, Perry B, Yao H, Strome R, Lieberburg I, Rommens J, Kim S, Schenk D, Fraser P, St George-Hyslop P, Selkoe DJ: Mutant presenilins of Alzheimer’s disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med 1997;3:67–72.
66.
Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, Yager D, Slunt HH, Wang R, Seeger M, Levey AI, Gandy SE, Copeland NG, Jenkins NA, Price DL, Younkin SG, Sisodia SS: Familial Alzheimer’s disease-linked presenilin 1 variants elevate Abeta1–42/1–40 ratio in vitro and in vivo. Neuron 1996;17:1005–1013.
67.
Xia W, Zhang J, Kholodenko D, Citron M, Podlisny MB, Teplow DB, Haass C, Seubert P, Koo EH, Selkoe DJ: Enhanced production and oligomerization of the 42-residue amyloid beta-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J Biol Chem 1997;272:7977–7982.
68.
Mehta ND, Refolo LM, Eckman C, Sanders S, Yager D, Perez-Tur J, Younkin S, Duff K, Hardy J, Hutton M: Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 1998;43:256–258.
69.
Wisniewski T, Golabek A, Matsubara E, Ghiso J, Frangione B: Apolipoprotein E: Binding to soluble Alzheimer’s beta-amyloid. Biochem Biophys Res Commun 1993;192:359–365.
70.
Poirier J: Apolipoprotein E and Alzheimer’s disease. A role in amyloid catabolism. Ann NY Acad Sci 2000;924:81–90.
71.
Davis JN, 2nd, Chisholm JC: The ‘amyloid cascade hypothesis’ of AD: Decoy or real McCoy? Trends Neurosci 1997;20:558–559.
72.
Joseph J, Shukitt-Hale B, Denisova NA, Martin A, Perry G, Smith MA: Copernicus revisited: Amyloid beta in Alzheimer’s disease. Neurobiol Aging 2001;22:131–146.
73.
Smith MA, Joseph JA, Perry G: Arson. Tracking the culprit in Alzheimer’s disease. Ann NY Acad Sci 2000;924:35–38.
74.
Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD: Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000;283:1571–1577.
75.
Butcher J: Alzheimer’s amyloid hypothesis gains support. Lancet 2000;356:2161.
76.
Davies P: A very incomplete comprehensive theory of Alzheimer’s disease. Ann NY Acad Sci 2000;924:8–16.
77.
Mesulam MM: A plasticity-based theory of the pathogenesis of Alzheimer’s disease. Ann NY Acad Sci 2000;924:42–52.
78.
Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000;71:621S–629S.
79.
de la Torre JC: Impaired cerebromicrovascular perfusion. Summary of evidence in support of its causality in Alzheimer’s disease. Ann NY Acad Sci 2000;924:136–152.
80.
Rogers J, Webster S, Lue LF, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P: Inflammation and Alzheimer’s disease pathogenesis. Neurobiol Aging 1996;17:681–686.
81.
Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T: Early-onset autosomal dominant Alzheimer disease: Prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664–670.
82.
Slooter AJ, Breteler MB, Ott A, Van Broeckhoven C, Van Duijn CM: APOE genotyping in differential diagnosis of Alzheimer’s disease. Lancet 1996;348:334.
83.
Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Liao Z, Lieberburg I, Motter R, Mutter L, Soriano F, Shopp G, Vasquez N, Vandevert C, Walker S, Wogulis M, Yednock T, Games D, Seubert P: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173–177.
84.
Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, Duff K, Jantzen P, DiCarlo G, Wilcock D, Connor K, Hatcher J, Hope C, Gordon M, Arendash GW: A beta peptide vaccination prevents memory loss in an animal model of Alzheimer’s disease. Nature 2000;408:982–985.
85.
Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, Chishti MA, Horne P, Heslin D, French J, Mount HT, Nixon RA, Mercken M, Bergeron C, Fraser PE, St George-Hyslop P, Westaway D: A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer’s disease. Nature 2000;408:979–982.
86.
Chen G, Chen KS, Knox J, Inglis J, Bernard A, Martin SJ, Justice A, McConlogue L, Games D, Freedman SB, Morris RG: A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer’s disease. Nature 2000;408:975–979.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.